Ming Liu

Prof. Dr. Ming Liu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Carbohydrate Polymers
Verified
Journal Article
Closed access
XLXuxiu Lu
Xuxiu Lu
LQLing Qin
Ling Qin
MGMeng Guo
Meng Guo
JGJiajia Geng
Jiajia Geng
SDSongtao Dong
Songtao Dong
MLMing Liu
Ming Liu

25 April 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MLMingfei Liu
Mingfei Liu
YWYuxuan Wang
Yuxuan Wang
HXHaixin Xiang
Haixin Xiang
MGMeng Guo
Meng Guo
SLShirong Li
Shirong Li
JYJingchun Yao
Jingchun Yao
Ulcerative colitis (UC) has attracted much attention for its negative influence on quality of life and increased risk of colorectal cancer. Chemical and biological drugs are currently the usual treatment for UC. These drugs always induce severe side effects, or patients might become resistant to these therapies. Therefore, new therapeutic options for UC are urgently needed. In this study, we discovered the inhibitory activity of the intestinal tryptophan metabolite indole-3-carboxaldehyde (3-IAld) in dextran sulfate sodium salt (DSS)-induced UC mice by targeting the TLR4/NF-κB/p38 signaling pathway. This compound effectively protected against colon length shortening and damage induced by DSS in the colon, notably reducing the severity of inflammation. The production of inflammatory factors of TNF-α, IL-6, and IL-1β was significantly attenuated when treating with 3-IAld in vivo and vitro. This might be attributed to inhibition of the TLR4/NF-kB/p38 signaling pathway. Moreover, 3-IAld could up-regulate the expression of ZO-1 and Occludin in vivo and vitro. Meanwhile, liquid chromatography mass spectrometry (LC-MS) results showed that 3-IAld could balance the aspartate and glutamate metabolism and the lysine degradation metabolism in the serum of DSS-induced colitis mice. In conclusion, 3-IAld ameliorated the intestinal barrier dysfunction and inflammatory response in DSS-induced UC mice, balanced amino acid metabolism, and inhibited the activation of the TLR4/NF-kB/p38 signaling pathway, thereby protecting mice with colitis.

1 March 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GWGuangwei Wu
Guangwei Wu
XQXin Qi
Xin Qi
XMXiaomei Mo
Xiaomei Mo
GYGuihong Yu
Guihong Yu
QWQiang Wang
Qiang Wang
Dehai LiDehai Li
Dehai Li

6 January 2022 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
XLXuxiu Lu
Xuxiu Lu
MLMingfei Liu
Mingfei Liu
HDHui Dong
Hui Dong
JMJinlai Miao
Jinlai Miao
DSDimitrios Stagos
Dimitrios Stagos
MLMing Liu
Ming Liu

1 October 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
XQXin Qi
Xin Qi
GLGe Liu
Ge Liu
LQLin Qiu
Lin Qiu
XLXiukun Lin
Xiukun Lin
MLMing Liu
Ming Liu

8 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WZWeiyi Zhang
Weiyi Zhang
QCQian Che
Qian Che
HTHongsheng Tan
Hongsheng Tan
XQXin Qi
Xin Qi
JLJing Li
Jing Li
MLMing Liu
Ming Liu
Four new antimycin alkaloids (1–4) and six related known analogs (5–10) were isolated from the culture of a marine derivedStreptomycessp. THS-55, and their structures were elucidated by extensive spectroscopic analysis. All of the compounds exhibited potent cytotoxicityin vitroagainst HPV-transformed HeLa cell line. Among them, compounds6–7were derived as natural products for the first time, and compound5(NADA) showed the highest potency. NADA inhibited the proliferation, arrested cell cycle distribution, and triggered apoptosis in HeLa cancer cells. Our molecular mechanic studies revealed NADA degraded the levels of E6/E7 oncoproteins through ROS-mediated ubiquitin-dependent proteasome system activation. This is the first report that demonstrates antimycin alkaloids analogue induces the degradation of high-risk HPV E6/E7 oncoproteins and finally induces apoptosis in cervical cancer cells. The present work suggested that these analogues could serve as lead compounds for the development of HPV-infected cervical cancer therapeutic agents, as well as research tools for the study of E6/E7 functions.